$heff's $tation of $tocks & $olid DD

[investor911]

BVTI - Consolidated DD

1. Special Report( BVTI): Customized Cancer Vaccines Finally (Maybe) Arrive- Jun 12 2009, 12:00 AM EST

http://www.genengnews.com/news/bnitem.aspx?name=56088213

2. BVTI - BiovaxID sale in EU (Named Patient Program)
(Courtesy , Poster on Yahoo Message Board)

IDIS Pharma in EUROPE (http://www.idispharma.com/showcontent.asp?CollectionID=@0000000004) has started the sale

of BiovaxID in EU on compassionate use basis. If you know anyone with NHL, please forward them contact info

below.
Good luck to all,

=======================================
Dear XXX,

Thank you for your e-mail and I can confirm that IDIS has started the BiovaxID Named Patient Program, Please request that your physician contacts our Global Sales Team at IDIS, using the contact details below, if further information is required as IDIS is only permitted to deal with qualified and verified medics and medical facilities:

E-mail - [e-mail]
Tel + 44 1932 824100
Fax + 44 1932 824300

Kind Regards
Colleen


3. BVTI: Presentation from European Society for Medical Oncology (ESMO)

http://www.esmo.org/fileadmin/media/presentations/826/LCT10001552.ppt

4. BVTI- PPT filed with the SEC- An important read

http://sec.gov/Archives/edgar/data/704384/000119312506152662/dex991.htm

Move to Slide # 10:

5.In addressing regulatory and commercial plans for BiovaxID, Biovest's President and General Counsel, Samuel Duffey, commented, "We have already initiated discussions with the FDA and EMEA and are preparing for further meetings with those agencies and other international regulatory authorities in order to share our significant results and determine the most appropriate approval regulatory pathways. In addition, we plan to make BiovaxID available throughout most of Europe on a named-patient basis. This compassionate-use drug access program allows European physicians to prescribe drugs to qualifying patients before approvals are granted, assuming the protocols for each participating country are followed."

6. Positive, Clinically Significant Phase III Results for Personalized Anti-Cancer Vaccine, BiovaxID(R),Presented at ASCO Plenary Session
Ref: http://investorshub.advfn.com/boards/read_msg.aspx?message_id=38300750

7. BVTI- Media BUZZ

7.a. Story from ABC NEWS
http://www.abcnews.go.com/Health/CancerPreventionAndTreatment/story?id=7718919&page=1

7.b. Video from NBC NEWS
http://www.msnbc.msn.com/id/21134540/vp/31030637#31030637

7.c. Article from NY Times
http://www.nytimes.com/2009/06/01/business/01drug.html?ref=business

7.d. Article from Houston Chronicle
http://www.chron.com/disp/story.mpl/front/6451203.html

From BiomedReports

http://biomedreports.com/articles/most-popular/1099-pink-bio-play-may-move-markets-with-cancer-vaccine.html


8. BVTI: These are impressive results and may indicate that BiovaxID will be one of the first vaccines approved by the U.S. Food and Drug Administration.

Ref: http://professional.cancerconsultants.com/oncology_main_news.aspx?id=43607